相关临床试验
1140
36 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
23
2.0%
已完成
989
86.8%
Enrolling By Invitation
8
0.7%
尚未招募
5
0.4%
招募中
59
5.2%
暂停
1
0.1%
终止
38
3.3%
Unknown
7
0.6%
撤回
10
0.9%
暂无批准数据
- UC Davis investigators have launched WE-CAIR, a multidisciplinary program to study how wildfire smoke drives cardiovascular and airway inflammation over the short and long term. - The initiative is backed by a five-year NIH Program Project Grant (P01 HL179398) from the National Heart, Lung, and Blood Institute totaling $14,050,840, including $8,993,941 in direct costs. - Four integrated projects will probe ILC2 immune cells, the aryl hydrocarbon receptor, the epigenetic regulator TET1, and the role of psychosocial stress and social vulnerability. - Studies estimate the number of people exposed to at least one day of extreme wildfire smoke annually has increased 27-fold over the past decade.
- Two studies following over 6,000 adults for 10 years found coronary artery calcium scores only modestly improved cardiovascular risk prediction when added to the PREVENT calculator. - In patients classified as borderline or intermediate risk by PREVENT, calcium scoring produced more meaningful reclassification of who would and would not have a heart attack or stroke. - Researchers cautioned that routine calcium scanning in low-risk people brings unnecessary radiation, testing and costs, while high-risk patients should start statins regardless of scan results. - A separate JACC analysis found some patients with a calcium score of zero still had events, indicating CAC should not be used to withhold statin therapy.
- Greenstone Biosciences received a Catalyze R61 award from the NIH's NHLBI to discover novel drug candidates targeting myocardial fibrosis and dilated cardiomyopathy in Duchenne muscular dystrophy. - DMD affects approximately one in every 3,500 baby boys worldwide, with cardiomyopathy representing the leading cause of death and no approved therapy directly addressing heart scarring. - The program leverages patient-derived iPSC cardiomyocyte models, unbiased proteomics, computational drug screening, and generative AI to identify and validate new drug candidates. - The award coincides with evolving regulatory support for New Approach Methodologies, including the FDA Modernization Act 3.0 passing the House and the FDA's permanent ISTAND program.
- UVA Health's Rachelle Crescenzi, PhD, received a $6.5 million NIH grant to develop SALT MRI, a non-invasive imaging approach for lymphedema and lipedema. - Lymphedema affects over 10 million Americans and up to 250 million people worldwide, yet patients often face misdiagnosis or delayed treatment due to limited diagnostic tools. - SALT MRI measures sodium, adipose tissue, and lymphatic fluids, with early findings showing tissue sodium increases with disease severity and decreases after physical therapy. - The seven-year project aims to establish a center for lymphatic disease research at UVA and develop objective diagnostic exams for earlier detection and personalized treatment.
- The FDA has approved Omisirge (Omidubicel-onlv) as the first cell therapy treatment for severe aplastic anemia, marking a significant milestone for patients with this rare blood disorder. - Clinical trial results showed 86% of patients achieved early and sustained neutrophil recovery at 100 days with a median recovery time of just 11 days. - The therapy demonstrated exceptional safety with no cases of severe acute or chronic graft-versus-host disease and achieved a 92% disease-free and overall survival rate. - Ayrmid plans to establish additional U.S. manufacturing capacity through a partnership with RoslinCT beginning in 2027 to meet expected patient demand.
- The FDA has accepted Ayrmid Ltd.'s priority review application for omidubicel as a treatment for severe aplastic anemia, with a PDUFA target action date of December 10, 2025. - Omidubicel is a nicotinamide modified allogeneic hematopoietic progenitor cell therapy derived from umbilical cord blood, already approved under the brand name Omisirge for hematologic malignancies. - Severe aplastic anemia affects 2-3 individuals per million and represents a significant unmet medical need for patients without matched sibling donors for transplantation. - The supplementary Biologics License Application is based on results from an investigator-sponsored study conducted at the National Heart, Lung, and Blood Institute of the National Institutes of Health.
- The FDA has approved HemiClor (12.5 mg chlorthalidone), the first low-dose formulation of this thiazide-like diuretic available in the U.S. for treating hypertension in adults. - The 12.5 mg dosage aligns with current ACC/AHA guideline recommendations and landmark clinical trials like ALLHAT and SHEP, which demonstrated cardiovascular outcome benefits with this starting dose. - HemiClor may help clinicians better individualize therapy and potentially reduce dose-related adverse effects such as hypokalemia and hyperuricemia, particularly beneficial for elderly patients.
- A new clinical trial shows adenotonsillectomy in children with mild sleep-disordered breathing reduces doctor visits by 32% and medication use by 48% within the first year after surgery. - Researchers found that for every 100 children who undergo the procedure, approximately 125 healthcare encounters and 253 prescriptions can be avoided in the year following surgery. - The benefits of tonsil and adenoid removal were more pronounced in children older than 5 years compared to younger patients, though the exact mechanisms behind the improvements remain under investigation.
- A comprehensive analysis of 4,527 clinical trials from 2015-2020 reveals that less than half of trials, whether NIH or industry-funded, focus on the top 20 childhood disease categories. - NIH funding proves crucial for pediatric research areas overlooked by industry, particularly in cancer and other critical childhood diseases, highlighting its vital role in advancing children's healthcare. - Key pediatric conditions including neonatal disorders, congenital birth defects, and asthma remain significantly underfunded relative to their disease burden, calling for increased research prioritization.
- The BEST-ICU trial, funded by NIH Collaboratory and NHLBI, investigates behavioral economics-based strategies to improve adoption of the evidence-based ABCDEF bundle in intensive care units. - Leading researchers Dr. Michele Balas and Dr. Ed Vasilevskis will present key protocol updates and implementation challenges at the upcoming PCT Grand Rounds on February 28, 2025. - The study aims to enhance team-based care delivery for critically ill adults across multiple healthcare systems through innovative implementation approaches.
